“Compound 15” is a BACE1 selective inhibitor with a fluoro-olefin replacement for an N-aryl amide without the liability of a potential aniline metabolite. The compound has good oral PK in rodents, which was likely challenging to obtain with the thioamidine core common to BACE1 inhibitors. As usual for Amgen there’s some pretty cool synthetic [...]
< 1 minute read
Sep. 18, 2021
Compound 15: A Selective BACE1 Protease Inhibitor
"compound 15"
selective BACE1 protease inhibitor oral PD demonstrated on Aβ in model from optimization of prior ligand Bioorg. Med. Chem. Lett., May 1, 2020 Amgen, Thousand Oaks, CA
Loading...
